Patent · US Active

Combination comprising immunostimulatory oligonucleotides

US11578331B2 · kind B2 · utility

0Cited by

28References

4Claims

0Family size

Assignee

Gilead Sciences, Inc. · US

Inventors

Matthias Schroff · Berlin, DE
Manuel Schmidt · Berlin, DE
Kerstin Kapp · Berlin, DE
Alfredo Zurlo · Berlin, DE

Key dates

Filing date	Feb 18, 2020
Grant date	Feb 14, 2023
Priority date	—
Expiry date	Feb 18, 2040

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/31
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAG3, CD137(4-1BB) and a non-coding immunomodulating DNA.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.